Alpine Immune Sciences Stock Fundamentals
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Alpine Immune Sciences fundamentals help investors to digest information that contributes to Alpine Immune's financial success or failures. It also enables traders to predict the movement of Alpine Stock. The fundamental analysis module provides a way to measure Alpine Immune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alpine Immune stock.
Alpine |
Alpine Immune Sciences Company Current Valuation Analysis
Alpine Immune's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alpine Immune Current Valuation | 4.16 B |
Most of Alpine Immune's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alpine Immune Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Alpine Immune Sciences has a Current Valuation of 4.16 B. This is 71.03% lower than that of the Biotechnology sector and 10.43% lower than that of the Health Care industry. The current valuation for all United States stocks is 74.97% higher than that of the company.
Alpine Immune Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alpine Immune's current stock value. Our valuation model uses many indicators to compare Alpine Immune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alpine Immune competition to find correlations between indicators driving Alpine Immune's intrinsic value. More Info.Alpine Immune Sciences is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alpine Immune's earnings, one of the primary drivers of an investment's value.Alpine Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alpine Immune's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alpine Immune could also be used in its relative valuation, which is a method of valuing Alpine Immune by comparing valuation metrics of similar companies.Alpine Immune is currently under evaluation in current valuation category among its peers.
Alpine Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X | |||
| Price To Book | 12.87 X | |||
| Price To Sales | 71.68 X | |||
| Revenue | 58.88 M | |||
| Gross Profit | (40.18 M) | |||
| EBITDA | (43.67 M) | |||
| Net Income | (32.18 M) | |||
| Cash And Equivalents | 167.86 M | |||
| Cash Per Share | 5.52 X | |||
| Total Debt | 9.91 M | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 2.75 X | |||
| Book Value Per Share | 5.08 X | |||
| Cash Flow From Operations | (79.01 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (0.64) X | |||
| Target Price | 62.0 | |||
| Number Of Employees | 142 | |||
| Beta | 0.97 | |||
| Market Capitalization | 4.46 B | |||
| Total Asset | 381.81 M | |||
| Retained Earnings | (256.14 M) | |||
| Working Capital | 288.05 M | |||
| Current Asset | 25.53 M | |||
| Current Liabilities | 3.39 M | |||
| Net Asset | 381.81 M |
About Alpine Immune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alpine Immune Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alpine Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alpine Immune Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |